Hexarelin
Research OnlyThe most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
Examorelin · HEX · Growth Hormone Releasing Hexapeptide · MF-6003 · EP-23905
18 human studies
- Preclinical
- 36%
- Clinical
- 43%
Based on 42 cited sources
clinically demonstrated · low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 61 (1A 28: several small human RCTs/controlled trials but all tiny n and largely Turin-clustered — Bisi 1999 RCT n=7 PMID:10342360, Maccario 2002 RCT PMID:11888836, Frieboes 2004 controlled trial PMID:15177700, Ghigo 1994 comparative PMID:8126144; 1B 11 "some concerns", no low-RoB clinical-outcome RCT or systematic review; 1C 6 total human N ~50-300 across small studies; 1D 8 partially direct — GH rise is direct PD but cardiac/sleep claims rest on surrogates; 1E 8 substantial multi-model preclinical program). Mechanism 84 (2A 35 GHS-R1a binding+functional plus CD36 cardiac target with PKC-inhibitor abolition of the cardioprotective effect, Frascarelli 2003 PMID:14556085; 2B 22 Gq/PLC/IP3/Ca2+ and CD36/PPAR-gamma chains largely mapped; 2C 17 monotonic dose-response in vivo in humans and rodents; 2D 10 confirmed in mammalian in vivo). Plausibility 82 (3A 28 mechanism->surrogate firmly established for GH and LVEF/infarct, surrogate->clinical benefit inferred; 3B 23 coherent with ghrelin/CD36 biology; 3C 18 multiple same-class GHRPs reliably raise GH; 3D 13 tightly scoped GH/cardiac/desensitization claims). Global Coverage 55 (4A 22 GH effect replicated across Turin, Munich, Pisa, Hong Kong; 4B 16 4+ countries incl. US co-authorship; 4C 17 ~42 sources, 20-100 studies across endocrine/cardiac/sleep/neuro; 4D 0 no regulatory approval anywhere, development discontinued). Community Experience 60 (5A 14 niche persistent GHRP-community use; 5B 23 >7-year track record; 5C 14 broadly consistent "potent but desensitizes" themes; 5D 9 isolated cortisol/prolactin/ hunger reports, no recurring serious signal). Effectiveness basis clinical (low): quantified human PD efficacy (GH AUC ~2x GHRH PMID:8126144; LVEF +6.7 points PMID:10342360) but surrogate-only endpoints, tiny samples, and rapid desensitization preventing durable/clinical benefit cap E2/E3/E4.
Hexarelin is the most potent synthetic growth hormone secretagogue, acting primarily through the ghrelin receptor (GHS-R1a). Unique among GHRPs, it also exhibits GH-independent cardioprotective effects via CD36 receptor binding.
How It Works (Simplified)
Hexarelin triggers powerful GH release but with a critical limitation - rapid desensitization:
Binds GHS-R1a on pituitary somatotrophs, triggering calcium release and potent GH secretion - in human studies roughly 2x the response to GHRH.
Uniquely binds CD36 on cardiomyocytes, activating PPAR-gamma and anti-apoptotic pathways independent of GH release.
High receptor affinity causes rapid receptor internalization - the GH response to repeated dosing is blunted, with no sustained IGF-1 elevation.
Minimal cortisol/prolactin elevation compared to GHRP-6/GHRP-2, though less selective than ipamorelin.
Key Research: Ghigo E et al. (Turin, 1994) characterized hexarelin’s GH-releasing activity across routes in human studies, showing a GH response about 2x greater than GHRH. PMID:8126144
Important Limitations
- Rapid desensitization (4-7 days) ended pharmaceutical development
- Cardioprotective effects primarily demonstrated in animal models
- No sustained IGF-1 elevation achievable with chronic dosing
- Long-term safety data limited due to desensitization preventing chronic exposure
- Not approved by any regulatory agency for therapeutic use
Research Tools
- Hexarelin Reconstitution Calculator — calculate concentration from vial mass and diluent volume (educational tool only)
Reported positives
- Strong GH release reported comparable to GHRP-6
- Cardioprotective properties noted in research
- Improved recovery and sleep quality reported
- Potent effects from relatively small amounts
Reported negatives
- Rapid desensitization with continued use
- Cortisol and prolactin elevation concerns
- Hunger increase though less than GHRP-6
- Limited long-term safety data
“Known as the most potent GHRP. Community notes rapid desensitization as major drawback.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
Based on human studies: GH peak occurs 15-30 minutes after subcutaneous or IV administration. GH response is approximately 2x greater than GHRH. Single-dose effects are potent and reliable.
PMID:8126144Initial doses maintain strong GH response. Subcutaneous administration achieves a GH response comparable to the IV route. Cardioprotective effects may occur with each dose independent of GH status.
PMID:8126144Desensitization develops with repeated dosing. The GH response to a subsequent dose is blunted and no rise in IGF-1 is achieved. This tolerance limited pharmaceutical development.
PMID:11888836Continued dosing produces a desensitized GH response. Recovery of sensitivity requires a washout period. This desensitization profile makes hexarelin unsuitable for chronic therapy.
PMID:9186261Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Tesamorelin
SynergisticGHRH+GHRP synergy - tesamorelin (GHRH) amplifies hexarelin's (GHRP) GH-releasing effect. However, hexarelin's rapid desensitization limits practical use of this combination.
Sermorelin
SynergisticClassic GHRH+GHRP synergy. Sermorelin (GHRH) and hexarelin (GHRP) produce greater GH release than either alone.
BPC-157
CompatibleDifferent mechanisms - hexarelin for GH release, BPC-157 for tissue repair. No known interactions.
GHRP-6
AvoidBoth are GHRPs acting on the same receptor (GHS-R1a). Combining provides no additional benefit and hexarelin desensitizes faster than GHRP-6.
GHRP-2
AvoidBoth are GHRPs targeting GHS-R1a. No benefit to combining as they share mechanism. Use one or the other.
Ipamorelin
AvoidBoth GHRPs acting on same receptor. Ipamorelin is more selective with less desensitization; combining offers no advantage.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Hexarelin
Related Peptides
CJC-1295
DAC:GRF · Modified GRF 1-29 · Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST · FS-344 · FS-315 +1
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
Human Chorionic Gonadotropin (hCG)
hCG · Choriogonadotropin · Pregnyl +5
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
HMG
Human Menopausal Gonadotropin · Menotropins · hMG +4
A urinary-derived glycoprotein hormone preparation containing both FSH and LH in approximately 1:1 ratio, FDA-approved for female infertility (ovulation induction, ART) and male hypogonadotropic hypogonadism. First used clinically in 1961 by Bruno Lunenfeld, HMG enabled the birth of the first American IVF baby in 1981 and remains a cornerstone of fertility medicine with over 60 years of clinical experience. Highly purified preparations (HP-hMG) demonstrate comparable or slightly superior live birth rates compared to recombinant FSH in IVF.
IGF-1 LR3
Long R3 IGF-1 · LR3-IGF-1 · Insulin-like Growth Factor 1 Long R3
A modified form of IGF-1 with an extended half-life due to reduced binding protein affinity. Used primarily in research for muscle growth and metabolic effects. Not approved for human use; significant safety concerns exist.
Kisspeptin
KISS1 · Metastin · Kisspeptin-54 +3
An endogenous neuropeptide that serves as the master regulator of reproductive function. Acts upstream of GnRH to control puberty, fertility, and the menstrual cycle. Under clinical investigation as a safer IVF trigger and treatment for hypothalamic amenorrhea. Pioneering research led by Imperial College London.